Study of Brain Imaging With Nuclear Technology in Individuals With Parkinsonian Syndrome
This study assesses dopamine transporter density using single photon emission computed tomography (SPECT) brain imaging with an investigational radiopharmaceutical, [123I]ß-CIT, in research participants with Parkinson's disease.
Procedure: [123I]ß-CIT and SPECT imaging
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
|Official Title:||Dynamic SPECT Imaging With [123I]ß-CIT in Patients With Parkinsonism|
- CIT uptake: measurement of dopamine transporter density compared with the clinical severity of illness
- Measurement of variability of strital uptake of [123I]ß-CIT when more than one scan has occurred
|Study Start Date:||September 1992|
|Estimated Study Completion Date:||August 2005|
The brain imaging is conducted at the Institute for Neurodegenerative Disorders in New Haven, Connecticut. The imaging procedure occurs over a two day period.
After a screening visit, including review of the potential subject's neurological history and a thorough neurologic exam, subjects are injected with [123I]ß CIT, an investigational radioactive material that localizes in the brain.
Twenty-four hours later study participants return to the Institute for Neurodegenerative Disorders where an investigational scanning procedure is used to obtain SPECT (single photon emission computed tomography) images of the brain.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00132626
|Principal Investigator:||Kenneth Marek, MD||Institute for Neurodegenerative Disorders|